First reaction: who comes up with these crazy

New Post Public Reply Private Reply Replies (0) Message Board
Drano Chemdeps #19522
First reaction: who comes up with these crazy unpronounceable un-remember-able names for these drugs? Geeze.

Their drug is administered subcutaneously according to first quote below, so it would be possible for people to self-inject, as with insulin for diabetics. However lots of people are afraid of needles, so I assume it would mean doctor's office visits for injections.

The second quote posted below indicates that this seems to be a once-every-two-weeks dosing, and they kept people on it for over a year.

So my conclusion is: Lilly's drug, unpronounceable, is much better than Enbrel and also much safer. It appears to require continuous injection over time.

My utterly unproven theory is that we group auto-immune diseases by symptoms into one category -- for instance, psoriasis -- but that disease may actually be triggered by several different causes. Therefore, certain drugs may work better on patients with one cause, and other drugs work better for patients with a different cause. (Or in the case of certain cancers, genetic differences among the patients -- we know this to be true.)

So:
IF, and it's a big if, Prurisol is effective and acts as it did in the animal studies, it would be preferable in because the number of doses would be less, and it shouldn't require maintenance doses every two weeks like the Lilly drug does.

The Lilly drug is being tested on moderate to severe psoriasis, and Prurisol is being tested on mild to moderate. So, it could be that Prurisol (IF IT WORKS) becomes the first-line treatment because of the (WE PRESUME) fewer doses needed for efficacy and maintenance. And, if P fails, then patients try the Lilly drug.

ALL speculation, of course. But there is plenty of room for many different treatments of a disease that affects so many people. Having options for patients who may respond better to one drug than another is a good thing, so I hope Lilly's drug works.... and that Prurisol works better. at least for mild-to-moderate stage patients.


Quote:

xekizumab, a humanized IgG4 monoclonal antibody administered by subcutaneous injection....

No serious adverse events occurred during the study, and the most common reported adverse events, similar to brodalumab, were nasopharyngitis, upper respiratory infection, injection site reactions and headaches. Asymptomatic, grade 2 neutropenia (i.e., 1000 to 1500 cells per cubic millimeter) occurred in two subjects on ixekizumab.

http://www.medscape.com/viewarticle/809459_5


Here's info on the phase 2 trial, from last year:

Quote:
According to Eli Lilly's statement, 78-90 percent of the patients taking ixekizumab experienced at least a 75 percent improvement in their psoriasis after twelve weeks, as measured by the Psoriasis Area and Severity Index (PASI 75). Of these patients, 31-41 percent achieved 100 percent improvement (PASI 100) after twelve weeks, which is clear skin.

In comparison, only 5-7 percent of patients taking Enbrel achieved PASI 100, the statement reports.UNCOVER, the study testing ixekizumab against a placebo only, kept patients on the drug for 60 weeks. Throughout the entire study period, patients maintained "high levels of response," according to the press release.

The most common side effects for ixekizumab were colds and infections around the site of the injection, and in the trials comparing ixekizumab with Enbrel, the frequency and severity of side effects were similar for the two drugs, according to the release.

https://www.psoriasis.org/advance/new-psorias...f-patients

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 101

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 79

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Sungrow Puts Storage Safety and Deployment on Display

Updated Category News Views 129

Fire-test footage is not usually the thing that grabs a room in Las Vegas, but Sungrow made it the centerpiece at RE+ 2026 for a reason. Energy storage has no shortage of glossy promises; what it needs is proof that equipment can handle the ugly stuff. Sungrow used the show to pitch a broader North American lineup, yet the PowerTitan 3.0 battery system and its large-scale...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 99

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Vanguard's Digital Win Matters More Than a Trophy

Updated Category News Views 104

A wealth manager’s website rarely earns applause, but a bad one can sure as hell lose trust fast. Vanguard’s move to No. 1 from No. 3 in the 2025 ranking for advised-investor website satisfaction is worth noticing because it hits the unglamorous part of wealth management that clients actually live with: checking accounts, understanding a plan, moving cash, and...

Continue Reading
Envision’s COP31 Pitch Hinges on Grid Execution, Not Targets

Updated Category News Views 93

A 2,500 GW traffic jam is a rotten place to park climate ambition. Envision Energy used COP31 in Antalya to make the more useful point: clean-power targets mean very little if grids cannot connect, balance and dispatch the electricity. Kane Xu’s message was not another round of flag-waving promises. It was an argument that the constraint has shifted from wanting...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 33

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 218

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 136

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
Mindgruve's Tech Hire Puts Sightline Growth in Focus

Updated Category News Views 23

Agency technology hires usually land with all the thunder of a stapler dropping, but this one deserves a closer look. Mindgruve has named Steve Terjeson vice president of technology, handing a former WPP Choreograph executive the job of leading its software development and data engineering teams. The assignment is not vague: push AI innovation, make the proprietary...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating 15 Years of Animal Rescue Corps' Impact

Updated Category News Views 307

Animal Rescue Corps Commemorates 15 Years of Impact Animal Rescue Corps (ARC), a dedicated national nonprofit organization, is excited to celebrate 15 remarkable years of rescuing animals and advocating for their protection. This milestone is not just a reflection of the past but a commitment to continue fighting for animals in need. To honor this achievement, ARC warmly...

Continue Reading
Investigating Investor Claims: Atara Biotherapeutics Update

Updated Category News Views 184

Investor Investigations into Atara Biotherapeutics Recent developments have led to significant interest from investors regarding Atara Biotherapeutics, Inc. (NASDAQ: ATRA). Allegations of possible securities fraud have prompted Pomerantz LLP to investigate the circumstances surrounding the company's practices. If you hold shares in Atara, it's crucial to stay informed...

Continue Reading
Systech's Remarkable 40-Year Journey in Pharma Packaging

Updated Category News Views 329

Systech Celebrates 40 Years of Industry Excellence Marking four decades of innovation, Systech has emerged as a key player in the field of packaging and serialization for the pharmaceutical industry. The company has developed a unique platform that alleviates the common frustrations of working with multiple vendors, providing a comprehensive solution that enhances...

Continue Reading
Empowering Black Artists: The BMAC LIVE Accelerator Initiative

Updated Category News Views 134

The Black Music Action Coalition Launches BMAC LIVE Accelerator Program The Black Music Action Coalition (BMAC) has officially announced the exciting return of its BMAC LIVE Accelerator Program. This initiative is designed to empower Black artists and professionals in the music industry by providing essential resources, training, and mentorship opportunities. BMAC...

Continue Reading
Imperial Petroleum Announces Series A Preferred Share Dividend

Updated Category News Views 212

Imperial Petroleum Inc. Declares Dividend on Series A Preferred Shares ATHENS, Greece – Imperial Petroleum Inc. (NASDAQ: IMPP), a prominent player in the maritime shipping industry, recently made headlines with the announcement of a dividend of $0.546875 per share on its 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock. This dividend is notably payable to...

Continue Reading